Get the Stockscreener App
24.04
0.23%
-0.123
Moderna Inc stock is traded at $24.04, with a volume of 5.15M.
It is down -0.23% in the last 24 hours and down -11.25% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$24.16
Open:
$24.22
24h Volume:
5.15M
Relative Volume:
0.46
Market Cap:
$9.41B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.7534
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-2.61%
1M Performance:
-11.25%
6M Performance:
-10.89%
1Y Performance:
-45.54%
1-Day Range:
$23.92
$24.63
1-Week Range:
$23.92
$26.05
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.09 | 9.44B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.93 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
736.43 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.27 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
912.96 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
210.13 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Responds to FDA Claims Regarding Vaccine Safety - GuruFocus
Prudential Financial Inc. Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Is Moderna Stock Underperforming the Nasdaq? - Yahoo Finance
Moderna stock falls after FDA vows to impose new vaccine requirements - The Boston Globe
S&P 500 Gains and Losses Today: Moderna Plunges; Synopsys Surges on Nvidia Deal - Investopedia
Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval - MarketScreener
Moderna Falls As FDA Vows To Impose New Vaccine Rules - MarketScreener
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Moderna stock slides as FDA moves to tighten vaccine guidelines - Proactive financial news
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More - Investopedia
Moderna (MRNA) Shares Drop Amid Stricter FDA Vaccine Approval St - GuruFocus
Stock Movers: Moderna, Synopsys, Barrick Mining - Bloomberg.com
Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals - Barron's
Moderna falls after FDA vows to impose new vaccine requirements - The Detroit News
Moderna, vaccine makers decline following FDA official comments on future approvals (MRNA:NASDAQ) - Seeking Alpha
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals - Tokenist
Here’s why Moderna is sliding - Traders Union
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barron's
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
Market movers: Charbone Hydrogen, Moderna, Synopsys... - Proactive financial news
Quadrature Capital Ltd Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Grantham Mayo Van Otterloo & Co. LLC Sells 508,235 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Moderna (MRNA) Leads Healthcare Gains with 16.19% Surge - GuruFocus
Rhumbline Advisers Acquires 25,390 Shares of Moderna, Inc. $MRNA - MarketBeat
FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules - Benzinga
FDA official Prasad says COVID shot deaths mean stricter vaccine approval standards - Seeking Alpha
Rockefeller Capital Management L.P. Decreases Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Inc. Stock Climbs 3.9%, Outperforms Peers - 富途牛牛
Moderna Must Face Northwestern Patent Suit Over Covid Vaccine - Bloomberg Law News
Tangible book value per share of Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs – BCBA:MRNA - TradingView
Swiss National Bank Sells 258,800 Shares of Moderna, Inc. $MRNA - MarketBeat
Legal & General Group Plc Sells 845,459 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Kitsap Sun
Take Profit: How buybacks impact Moderna Inc. stock valueJuly 2025 Macro Moves & Weekly Setup with ROI Potential - moha.gov.vn
Jefferies Financial Group Inc. Sells 109,640 Shares of Moderna, Inc. $MRNA - MarketBeat
Where Will Vertex Pharmaceuticals Be in 5 Years - The Motley Fool
Handelsbanken Fonder AB Sells 62,447 Shares of Moderna, Inc. $MRNA - MarketBeat
Ensign Peak Advisors Inc Has $3.42 Million Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces Data to be Presented at ESMO Congress 2025 - Montgomery Advertiser
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - Daytona Beach News-Journal
Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating - MarketScreener
(MRNA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Moderna Secures $1.5 Billion Credit Facility - The Globe and Mail
Moderna, Inc. $MRNA Shares Sold by Nomura Asset Management Co. Ltd. - MarketBeat
Moderna exec explains shift to onshore manufacturing, Norwood investment - The Business Journals
Entropy Technologies LP Invests $552,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Independent Mail
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):